Logo of Gesundheitsinformation.de

Ozanimod (Zeposia) for the treatment of multiple sclerosis

Ozanimod (Zeposia) for the treatment of multiple sclerosis

Ozanimod (Zeposia) for the treatment of relapsing multiple sclerosis without a high level of disease activity

In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether ozanimod (trade name: Zeposia) has any advantages or disadvantages compared to interferon beta-1a for the treatment of active relapsing-remitting multiple sclerosis (RRMS) in people who have not had previous treatment or in people who have already had treatment and whose multiple sclerosis is not highly active.

For this assessment, the manufacturer provided two studies involving a total of 1,480 people. 737 of these participants had treatment with interferon beta-1a, and 753 were given ozanimod. The following results were found after one year:

What are the advantages of ozanimod?

Relapses: The studies show that ozanimod has an advantage here: Relapses were less common in people who used ozanimod than they were in those who used interferon beta-1a.

What are the disadvantages of ozanimod?

The studies did not find that ozanimod had any disadvantages compared to interferon beta-1a.

No difference

There was no difference between treatment with ozanimod and treatment with interferon beta-1a in terms of the following aspects:

  • Life expectancy: There were no deaths in either of the groups within one year.
  • Worsening of disability
  • Severity of disability
  • Vision
  • Health-related quality of life
  • Severe side effects
  • Treatment stopped due to side effects: About 2 to 3 out of 100 people in each group stopped their treatment due to side effects.

What remains unanswered?

Fatigue: The manufacturer did not provide any data on this aspect.

The specific side effects could also not be assessed using the data supplied to IQWiG.

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ozanimod (multiple sclerosis) – benefit assessment according to § 35a SGB V. Dossier assessment; Commission A20-59. October 13, 2020. (IQWiG reports; Volume 980).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas - either via our form or by gi-kontakt@iqwig.de. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?”

Print page

Ozanimod (Zeposia) for the treatment of relapsing multiple sclerosis without a high level of disease activity

Über diese Seite

Updated on November 5, 2020

Next planned update: 2023

Publisher:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

Stay informed

Subscribe to our newsletter or newsfeed. You can find our growing collection of films on YouTube.

Print page